News
AQST
3.500
-0.57%
-0.020
Weekly Report: what happened at AQST last week (0429-0503)?
Weekly Report · 15h ago
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
NASDAQ · 16h ago
Aquestive Therapeutics Earns Buy Rating on Libervant’s Pediatric Approval and Anaphylm’s Market Potential
TipRanks · 6d ago
Aquestive stock falls amid Libervant approval, Anaphylm update
Shares of Aquestive Therapeutics were down 12% in early afternoon trading Monday. The company said it has received FDA approval for pediatric use of its drug Libervant. The firm expects to file for approval of its new drug Anaphylm at the end of 2024.
Seeking Alpha · 04/29 17:56
12 Health Care Stocks Moving In Monday's Intraday Session
Deciphera Pharmaceuticals (NASDAQ:DCPH) stock moved upwards by 72.2% to $25.22 during Monday's regular session. The company's Q1 earnings report came out today. Deciphera shares rose to $2.0 billion. SINTX Techs and Koninklijke Philips also moved upwards.
Benzinga · 04/29 16:31
ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings among healthcare movers
Healthcare On the Move ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings among healthcare movers. S&P 500 Health Care Sector +0.52% to 1639.33. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 04/29 14:02
Lake Street Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)
TipRanks · 04/29 12:55
Weekly Report: what happened at AQST last week (0422-0426)?
Weekly Report · 04/29 11:46
AQUESTIVE THERAPEUTICS INC: ANNOUNCES IMMEDIATE AVAILABILITY OF LIBERVANT 5MG, 7.5MG, 10MG, 12.5MG, AND 15MG FOR PATIENTS BETWEEN 2 TO 5 YEARS OF AGE
Reuters · 04/29 11:00
AQUESTIVE THERAPEUTICS RECEIVES U.S. FDA APPROVAL AND MARKET ACCESS FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM IN PEDIATRIC PATIENTS AGES 2 TO 5 AND PROVIDES UPDATE ON ANAPHYLM™ (EPINEPHRINE) SUBLINGUAL FILM
Reuters · 04/29 11:00
Buy Rating Affirmed for Aquestive Therapeutics Following FDA Approval and Growth Prospects
TipRanks · 04/29 04:25
Aquestive wins FDA approval for anti-seizure therapy Libervant
Healthcare Aquestive wins FDA approval for anti-seizure therapy Libervant. Libervant is a diazepam formulation developed as an oral rescue therapy for the treatment of seizures. The FDA granted tentative approval for the drug in August 2022. Aquestives Therapeutics, Inc. (AQST)
Seeking Alpha · 04/27 12:09
FDA APPROVES AQUESTIVE THERAPEUTICS' LIBERVANT- WEBSITE
Reuters · 04/26 20:54
Aquestive Therapeutics Inc <AQST.OQ> expected to post a loss of 8 cents a share - Earnings Preview
Aquestive Therapeutics Inc expected to post a loss of 8 cents a share. The company is expected to report a 10.1% increase in quarterly revenue to $12.262 million. The Warren New Jersey-based company will report results on May 7 for the period ending March 31 2024.
Reuters · 04/26 12:01
Aquestive Therapeutics: Notice of Effectiveness
Press release · 04/24 19:19
OPI, RVNC and AQST are among after hour movers
On the Move OPI, RVNC and AQST are among after hour movers. Cadence Design Systems and Synopsys are among the companies losing ground. Oportun Financial and Humacyte are the biggest gainers in this week's list of names on the move.
Seeking Alpha · 04/22 20:53
Weekly Report: what happened at AQST last week (0415-0419)?
Weekly Report · 04/22 11:33
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
Ally Financial shares jumped 7.7% to $39.06 on Thursday after the company reported better-than-expected quarterly results. The Nasdaq Composite fell over 50 points in today's session. Shares of Trump Media & Technology Group Corp. Also rose sharply.
Benzinga · 04/18 17:58
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
FDA approval is the number one needle mover for drug stocks. FDA approval for a drug or treatment can bring years of steady, high-margin revenue to a company. Three companies are awaiting key FDA decisions over the next couple of months. Merck & Co, Amgen and Aquestive Therapeutics are among the companies awaiting key decisions.
Investorplace · 04/17 12:00
Weekly Report: what happened at AQST last week (0408-0412)?
Weekly Report · 04/15 11:24
More
Webull provides a variety of real-time AQST stock news. You can receive the latest news about Aquestive Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.